Kronos Bio provides update on review of strategic alternatives

The company said, “As announced on November 13, 2024, Kronos Bio (KRON) is exploring strategic alternatives for the Company and its remaining internally developed preclinical assets. One potential scenario could include partnering the two p300 lysine acetyltransferase (KAT) inhibitor programs: an oncology candidate, KB-9558, for multiple myeloma and HPV-driven cancers expected to be IND-ready by the end of 2024, and an autoimmune disease candidate, KB-7898, for Sjogren’s disease which has begun IND-enabling studies.”